Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2016
Novartis LEE011 (ribociclib) granted FDA priority review for first-line treatment of HR+/HER2- advanced breast cancer
1 November 2016 - A marketing authorization application for LEE011 plus letrozole has also been accepted for review by the ...
Posted by Michael Wonder on 31 Oct 2016
As health premiums jump, Obama wields an imperfect shield
30 October 2016 - Urging people to sign up for coverage under the Affordable Care Act, President Obama said last ...
Posted by Michael Wonder on 30 Oct 2016
Roche announces FDA approval for Ventana PD-L1 (SP142) assay to support immunotherapy treatment decisions in lung cancer
27 October 2016 - First FDA-approved test to support patient treatment decisions for Tecentriq (atezolizumab) in non-small-cell lung cancer. ...
Posted by Michael Wonder on 29 Oct 2016
FDA approves new device for prevention of recurrent strokes in certain patients
28 October 2016 - The U.S. FDA today approved the Amplatzer PFO Occluder device. ...
Posted by Michael Wonder on 29 Oct 2016
Sanofi and Regeneron receive complete response letter from FDA for sarilumab, an investigational treatment for rheumatoid arthritis
28 October 2016 - Sanofi and Regeneron Pharmaceuticals today announced the U.S. FDA issued a complete response letter regarding the ...
Posted by Michael Wonder on 28 Oct 2016
Humana spells out its conditional Exondys 51 coverage policy — strings attached
27 October 2016 - Humana’s decision to cover Sarepta’s controversial Duchenne muscular dystrophy drug Exondys 51 (eteplirsen) comes with some ...
Posted by Michael Wonder on 28 Oct 2016
Drug prices, not the health law, top voters’ health priorities for 2017
27 October 2016 - Until this week, when big increases in insurance premiums were unveiled for next year, the federal ...
Posted by Michael Wonder on 28 Oct 2016
The best way to save Obamacare
27 October 2016 - The Affordable Care Act has faced a rocky six months. ...
Posted by Michael Wonder on 28 Oct 2016
In Washington’s drug price fight, plenty of blame to go around
27 October 2016 - Drug price legislation could be attached to FDA bill next year. ...
Posted by Michael Wonder on 28 Oct 2016
Health law tax penalty? I’ll take it, millions say
26 October 2016 - The architects of the Affordable Care Act thought they had a blunt instrument to force people ...
Posted by Michael Wonder on 26 Oct 2016
Crunch time for Obamacare
26 October 2016 - Big rises in premiums will cause most pain away from the exchanges. ...
Posted by Michael Wonder on 26 Oct 2016
Affordable Care Act premium increases are a fixable problem
25 October 2016 - The Affordable Care Act has improved and expanded health insurance to cover millions more Americans. ...
Posted by Michael Wonder on 26 Oct 2016
Seizing on rising costs, Trump says health law is ‘over’
25 October 2016 - Donald J. Trump, desperate for a winning political issue in the final two weeks of the ...
Posted by Michael Wonder on 26 Oct 2016
Novartis CEO sees tougher U.S. drug pricing over next three-five years
25 October 2016 - Novartis expects a more difficult pricing environment for drugs in the United States in the years ...
Posted by Michael Wonder on 26 Oct 2016
Slavitt says tackling drug spending will be top priority for next CMS leader
25 October 2016 - The next leader of the Centers for Medicare and Medicaid Services will have to make drug ...